Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Recurrent or Refractory Osteosarcoma
NCT02470091Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Nov 2015
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of denosumab in osteosarcoma (OS), sponsored by Children's Oncology Group. Started Nov 2015; status: completed.
02
Drugs
denosumab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT02470091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470091.